Vitamin D3 Analogues

The present invention is based on the unexpected finding that the A-ring portion of vitamin D.sub.3 analogues can be modified without negatively affecting the biological activity of the resulting compounds. In its broadest aspects, the invention provides vitamin D.sub.3 analogues which include at least one hydroxyalkyl substituent on the ring-A. It is contemplated that this hydroxyalkyl substituent may be placed on the 1, 2, 3- and/or 4- positions of the A-ring. However, the preferred embodiment of the invention is the vitamin D.sub.3 analogue wherein the 1.alpha.-hydroxy group is replaced by a hydroxyalkyl group of, for example, 1-6 carbon atoms. Structurally, the preferred D.sub.3 analogues of the invention may be shown as follows: ##STR2## including the stereoisomers thereof, wherein R is --R.sup.3 OH, R.sup.3 being straight or branched alkyl of 1 to 6 carbons; R.sup.1 is hydrogen and R.sup.2 represents the substituents completing a vitamin D.sub.3 analogue. Description (Set) Proposed Use (Set) The present invention relates to novel biologically active vitamin D.sub.3 analogues which include at least one hydroxyalkyl substituent in the 1-position. More specifically, the present invention relates to a compound YB which is a vitamin D.sub.3 analogue which includes a hydroxyalkyl substituent in the 1-position and a modified D-ring side chain. Compound YB is a potent anti-proliferative vitamin D.sub.3 analogue but has a very low (.about.10.sup.-3 relative to calcitriol) binding affinity to the calf thymus vitamin D.sub.3 receptor (VDR). Patent (Set) 5,274,142; 105029; 5,403,832; 5,389,622

Inventor(s): Posner, Gary H

Type of Offer: Licensing



« More Pharmaceutical Patents

---